Isomorphic Labs
AI-driven drug design and discovery
About
Founded in 2021 within Alphabet, Isomorphic Labs is an AI-first drug design and development company. It leverages advanced AI technology to autonomously design new drug candidates and advance therapeutic programs into clinical stages. The company's business model focuses on using its proprietary AI platform to innovate drug discovery, aiming to reduce time and cost in bringing novel therapies to market. Major funding rounds include $600M in its first external raise and a subsequent $2.1B Series B led by Thrive Capital, enabling global scaling and pipeline progression across multiple therapeutic areas.
Products
-
Drug Design Engine
— AI-powered platform that accelerates drug discovery by modeling biological processes and designing novel molecules.
Customer sectors: pharmaceutical companies, biotech researchers, drug discovery scientists
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Isomorphic Labs — available to members.
